PT  - JOURNAL ARTICLE
AU  - David O. Bates
AU  - Jonathan C. Morris
AU  - Sebastian Oltean
AU  - Lucy F. Donaldson
ED  - Garland, Christopher J.
TI  - Pharmacology of Modulators of Alternative Splicing
AID  - 10.1124/pr.115.011239
DP  - 2017 Jan 01
TA  - Pharmacological Reviews
PG  - 63--79
VI  - 69
IP  - 1
4099  - http://pharmrev.aspetjournals.org/content/69/1/63.short
4100  - http://pharmrev.aspetjournals.org/content/69/1/63.full
SO  - Pharmacol Rev2017 Jan 01; 69
AB  - More than 95% of genes in the human genome are alternatively spliced to form multiple transcripts, often encoding proteins with differing or opposing function. The control of alternative splicing is now being elucidated, and with this comes the opportunity to develop modulators of alternative splicing that can control cellular function. A number of approaches have been taken to develop compounds that can experimentally, and sometimes clinically, affect splicing control, resulting in potential novel therapeutics. Here we develop the concepts that targeting alternative splicing can result in relatively specific pathway inhibitors/activators that result in dampening down of physiologic or pathologic processes, from changes in muscle physiology to altering angiogenesis or pain. The targets and pharmacology of some of the current inhibitors/activators of alternative splicing are demonstrated and future directions discussed.